# Cetrelimab

Source: https://onco.cc/drugs/cetrelimab/  
OnCo record `cetrelimab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cetrelimab is an experimental investigational agent whose form is not stated in the registry from Janssen Research & Development in phase 3 trials for bladder & urothelial cancer, prostate cancer and non-small-cell lung cancer, with its target not yet stated publicly.

## Summary

Cetrelimab (JNJ-63723283) is an investigational agent whose form is not stated in the registry developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants will receive intravenous Cetrelimab. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder) and NCT05714202 (A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)), in bladder & urothelial cancer, prostate cancer and non-small-cell lung cancer. The largest, NCT05714202, plans to enrol 1135 participants (actual) with primary completion expected 2029-09-18. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: JNJ-63723283
- Modality: antibody (INN stem -mab; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of Cetrelimab: https://clinicaltrials.gov/search?intr=JNJ-63723283

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- trials: [A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer](https://onco.cc/trials/nct05908734/), [A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer](https://onco.cc/trials/nct03473743/), [A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer](https://onco.cc/trials/nct03431350/), [A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)](https://onco.cc/trials/hr-nmibc/), [A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder](https://onco.cc/trials/nct04658862/), [A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers](https://onco.cc/trials/nct02908906/)

---
JSON: https://onco.cc/api/v1/entities/cetrelimab.json